Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2021
Price :
$35
*
At a glance
- Drugs Soticlestat (Primary)
- Indications Complex regional pain syndromes; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Tuberous sclerosis
- Focus Adverse reactions; First in man
- Sponsors Takeda
- 09 Apr 2021 Results published in the British Journal of Clinical Pharmacology.
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology.
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.